Navigation Links
Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Date:5/19/2008

CLINTON, N.J., May 19 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that it has completed dosing of its Phase 1a trial for its drug candidate, IK-1001 (sodium sulfide) for injection.

The study was a Phase 1, randomized, single blind, placebo-controlled, single center dose escalation study of a single bolus injection of IK-1001 in healthy volunteers to assess safety, tolerability and pharmacokinetics. The study comprised five dosing cohorts of 0.005 mg/kg, 0.01 mg/kg, 0.03 mg/kg, 0.06 mg/kg and 0.1 mg/kg with four subjects in the first cohort and eight subjects in the remaining cohorts. Subjects were monitored for adverse events. Blood and urine were sampled to determine pharmacokinetic profiles. Doses evaluated were expected to be within the therapeutic window based on preclinical animal models. At the doses tested, no adverse reactions were observed that were of clinical significance, and no clinical laboratory abnormalities were detected. The trial was conducted in Melbourne, Australia and involved a total of 36 healthy volunteers.

Ralf Rosskamp, M.D., Executive Vice President for Research and Development of Ikaria, commented, "We are very pleased with these preliminary results, which suggest that IK-1001 is a well tolerated drug at the doses tested in healthy volunteers. Pre-clinical data have demonstrated the therapeutic potential of sodium sulfide for injection as a treatment for multiple hypoxic/ischemic conditions, including myocardial infarction, cardiopulmonary bypass surgery, and acute lung injury. In conjunction with this Phase 1a trial utilizing a single bolus injection, and an ongoing second, parallel Phase 1 study utilizing a single infusion regimen to be completed in July 2008, a dose regimen can be selected for Phase 2a. With the results of both studies in hand, we will begin planning for Phase 2a trials, which, pending discussions and approval from the appropriat
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
3. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
5. Cardinal Health Completes Enturia Acquisition
6. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
7. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
8. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
9. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
(Date:4/23/2015)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... on Thursday, May 7, 2015, after the close of ... audio webcast immediately following the announcement at 4:30 p.m. ... results and provide a business and financial update. ... via the Investors & Media section of the Jazz ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2
... 2010 TechniScan, Inc. (OTC Bulletin Board: ... development and commercialization of an automated breast ultrasound imaging system, ... TechniScan entered into amendments with each note holder, effective as ... its entire portfolio of secured convertible promissory notes from October ...
... 8, 2010 Arstasis is pleased to announce that ... Registry Evaluating Closure Following Access with the Arstasis One ... anticipated to enroll up to 500 patients in at ... is to observe the clinical safety and effectiveness of ...
Cached Medicine Technology:TechniScan, Inc. Announces Restructuring of Convertible Debt 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 3
(Date:4/24/2015)... New York (PRWEB) April 24, 2015 ... to move forward in the federal multidistrict litigation ... Carolina. According to court documents, the parties involved ... on April 16th detailing, among other things, preparation ... notes that counsel for both plaintiffs and defendants ...
(Date:4/24/2015)... 24, 2015 The first step to ... mind. , For meditation and yoga teacher Stine Koppernæs, ... been invaluable tools that allow her to experience more ... has been a teacher since 2006, and through the ... state of being. , “I love sharing this way ...
(Date:4/24/2015)... 24, 2015 Anchor Health Administrators (Anchor), ... Professionals, today announced their exclusive agreement with LTC Solutions ... Care Insurance distribution partner. , Anchor has more than ... Insurance benefits for associations, and is currently the designated ... Long Term Care Insurance member benefit. , “I am ...
(Date:4/24/2015)... Fla. (PRWEB) April 24, 2015 “Kind,” ... healer” were among the ways Denise Weiner described pediatric ... who cared for her daughter, Alexa, during her five-year ... brain resections, a bone marrow transplant and numerous experimental ... house to visit Alexa when she was not in ...
(Date:4/24/2015)... National Access Cannabis (NAC), Canada’s ... medical cannabis, is taking a leadership role in ensuring ... , NAC is the first to back mdBriefCase Group ... NAC will be providing 300 healthcare professionals with free ... help Canadians gain safe and responsible access to medical ...
Breaking Medicine News(10 mins):Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
... Awareness,Week approaches, 2009 brings yet another year of unhealthy ... Americans, including men and,boys. , ... eating,disorders is so important because hundreds of thousands of ... even consider an eating,disorder as a diagnosis for a ...
... and ,e-commerce feature to company Web site - www.geritrex.com . ... ... -- The Geritrex Corporation, a privately held pharmaceutical company that offers ... business. Founded by CEO and registered pharmacist Anthony Madaio, Geritrex ...
... tests for devastating conditions, report says , , WEDNESDAY, Feb. 18 ... three babies in the United States was born in a ... of conditions. But by the end of 2008, all 50 ... rules requiring newborn screening for at least 21 disorders, a ...
... RIVER, N.Y., Feb. 18 Tesia-PCI has successfully ... with United Concordia Companies, Inc., a national dental ... took just over two months from plan to ... experience and expertise helped United Concordia to avoid ...
... was announced today that,Medizone International,s (Pink Sheets: MZEI) ... direction of Dr. Michael E.,Shannon of the Canadian ... President of the Canadian Foundation for Global Health. ... Medizone International and is the Company,s,Director of Medical ...
... continues to present its myriad of challenges, SunStone ... cost cutting measures including cutbacks in capital projects, ... direct patient contact such as marketing, community, and ... easier layers to peel in these expense reduction ...
Cached Medicine News:Health News:Remuda Ranch Seeks to Increase Awareness of Eating Disorders Among Males During National Eating Disorders Awareness Week (NEDAW), February 22-28, 2009 2Health News:A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels 2Health News:Newborn Screenings Now Required Across U.S. 2Health News:Newborn Screenings Now Required Across U.S. 3Health News:National Dental Insurer United Concordia Successfully Launches Real-Time Claims Processing with Tesia-PCI 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 3Health News:The Marketing Enigma 2
... occlusive wrap than VICRYL knitted mesh. Especially ... be contained. Predictable absorption. Polyglactin 910 has ... nonpyrogenic. ,VICRYL (polyglactin 910) woven mesh is ... glycolide and lactide, derived respectively from glycolic ...
... Line Reinforcement Material is a safe, ... air leaks and as such, the ... biocompatible, ePTFE material requires no pretreatment ... load and fire and the material's ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... ProLite Ultra™, the next generation of thin ... hernia surgery and general soft tissue repair. ... better handling and more flexible polyproplylene mesh, ... ProLite Ultra. Its unique Litemesh™ polypropylene microfilament ...
Medicine Products: